CRISPR/Cas9 technology generated a leucine to glutamic acid substitution at amino acid 106 (p.L106E) targeting SYCP1s head-to-head interface. This corresponds to human L109. (J:342558)
Legend:
cx: complex: > 1 genome feature ot: other: hemizygous, indeterminate,... (F): Female
(M): Male
N: normal phenotype
(#): related diseases count